"Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: A cost-effectiveness analysis in Japan

Journal of Gastroenterology

Volumn 40, Issue 11, 2005, Pages 1029-1035

  Habu, Yasuki ^a,b   Maeda, Kazuo ^a   Kusuda, Takeo ^a   Yoshino, Takuya ^a   Shio, Seiji ^a   Yamazaki, Maki ^a,b   Hayakumo, Takanobu ^a,b   Hayashi, Kyohei ^c   Watanabe, Yoshiyuki ^c   Kawai, Keiichi ^b,d  

^a Saiseikai Noe Hospital   (Japan)

^b Digestive Clinical Outcomes Research Group   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d Yukawa Hospital   (Japan)

Author keywords

Cost effectiveness; Gastroesophageal reflux disease; Lansoprazole; Proton pump inhibitor; Reflux esophagitis

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGOSCOPY; HUMAN; INTERMETHOD COMPARISON; JAPAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROBABILITY; REFLUX ESOPHAGITIS; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ESOPHAGITIS, PEPTIC; HISTAMINE H2 ANTAGONISTS; HUMANS; JAPAN; MODELS, STATISTICAL; OMEPRAZOLE; PROTON PUMPS; RANITIDINE;

EID: 30344441246     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-005-1704-y     Document Type: Article

References (28)

1. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122:1500-1511 11984534
2. Furukawa N, Iwakiri R, Koyama T, Okamoto K, Yoshida T, Kashiwagi Y, et al. Proportion of reflux esophagitis in 6010 Japanese adults. J Gastroenterol 1999;34:441-444 10452674 1:STN:280:DyaK1MznvFOnsQ%3D%3D
3. Endo M, Kobayashi S, Suzuki H, Takemoto T, Nakayama K. Diagnosis of early esophageal cancer. Endoscopy 1971;2:61-66
4. DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med 1995;155:2165-2173 7487238 1:STN:280:BymD2cfps1I%3D
5. Freston J.W. Future prospects for proton pump inhibitors. Aliment Pharmacol Ther 1993;7(Suppl 1):68-75 8490082
6. Reynolds JC. Individualized acute treatment strategies for gastroesophageal reflux disease. Scand J Gastroenterol 1995;30(Suppl 213):17-24
7. Beck JR, Pauker SG. The Markov model in medical prognosis. Med Decis Making 1983;3:419-458 6668990 1:STN:280:BiuC2c7gtFQ%3D
8. 2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995;40:590-597 7895551 1:STN:280:ByqB3czgtlU%3D
9. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Evidence from randomized clinical trials. Clin Ther 2001;23:998-1017 11519776 1:CAS:528:DC%2BD3MXmsVykt7c%3D
10. Kishi S, Takemoto T, Tsuneoka K, Namiki M, Ishikawa M, Oshiba S. Evaluation of clinical usefulness of ranitidine on reflux esophagitis (in Japanese). Medical Consultation and New Remedies 1982;19:2978-2986
11. Kishi S, Ito S, Kajimoto Y, Mori H, Sawada S, Wada H, et al. Evaluation of clinical usefulness of lansoprazole on reflux esophagitis (in Japanese). Prog Med 1990;10:3197-3206
12. Sekiguchi T, Matsuzaki T, Horikoshi T, Kusano M. Open study of the clinical effects of lansoprazole in the treatment of reflux esophagitis. Drug Invest 1992;4:422-434
13. +-ATPase inhibitor: A controlled, double-blind study. Am J Gastroenterol 1993;88:1212-1217 8101695 1:STN:280:ByyA3s3gsVw%3D
14. Robinson M, Sahba B, Avner D, Jhalas N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995;9:25-31 7766740 1:STN:280:ByqB1cvhvF0%3D
15. Bardhan KD, Hawkey CJ, Long RG, Morgan AG, Wormsley KG, Moules IK, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1995;9:145-151 7605854 1:STN:280:ByqA38blsV0%3D
16. 2-receptor antagonist therapy. Am J Gastroenterol 1997;92:429-437 9068463 1:CAS:528:DyaK2sXitFeisrs%3D
17. Jansen JB, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Aliment Pharmacol Ther 1999;13:1611-1620 10594396 1:CAS:528:DC%2BD3cXltFWnug%3D%3D
18. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand J Gastroenterol 1988;23:625-632 3041558 1:STN:280:BieB1M%2Flt1Q%3D
19. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment of omeprazole. Gastroenterology 1988;95:903-912 3044912 1:STN:280:BieA3Mzlt1c%3D
20. Bate CM, Booth SN, Crowe JP, Mountford RA, Keeling PW, Hepworth-Jones B, et al. Omeprazole 10mg or 20mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995;36:492-498 7737552 1:STN:280:ByqB2MrntVE%3D
21. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:859-867 8610914 1:CAS:528:DyaK28XjtFKisrs%3D
22. Hegarty JH, Halvorsen L, Hazenberg BP, Nowak A, Smith CL, Thomson AB, et al. Prevention of relapse in reflux esophagitis: A placebo controlled study of ranitidine 150mg bid and 300mg bid. Can J Gastroenterol 1997;11:83-88 9113805 1:STN:280:ByiB283ntlY%3D
23. Sonnenberg A. Costs of medical and surgical treatment of duodenal ulcer. Gastroenterology 1989;96:1445-1452 2565844 1:STN:280:BiaB3s3lsF0%3D
24. Sakaguchi M, Ashida K, Habu Y, Tsuji S, Nebiki H, Masuda E, et al. Understanding and treatment of gastroesophageal reflux disease (GERD) and symptomatic gastroesophageal reflux disease (S-GERD): Examination by a questionnaire survey (in Japanese). Gastroenterology (Tokyo) 2004;39:330-340
25. Bate CM, Richardson PDI. A 1 year model for the cost-effectiveness of treating reflux esophagitis. Br J Med Econ 1992;2:5-11
26. Hillman AL, Bloom BS, Fendrik AM, Schwartz JS. Cost and quality effects of alternative treatment for persistent gastroesophageal reflux disease. Arch Intern Med 1992;152:1467-1472 1627026 1:STN:280:By2A38fmtFI%3D
27. Jonsson B, Stalhammer N-O. The cost effectiveness of omeprazole and ranitidine in intermittent and maintenance treatment of reflux esophagitis - The case of Sweden. Br J Med Econ 1993;6:111-126
28. Hongo M. Reflux esophagitis and Helicobacter pylori: East and West. J Gastroenterol 2004;39:909-910 15565416